RA PHARMACEUTICALS

ra-pharmaceuticals-logo

Ra Pharma is developing Cyclomimetics, a new drug class with the diversity and specificity of antibodies, coupled with the many benefits of small molecules. Ra Pharma is leveraging its ability to rapidly generate drug candidates to develop its own portfolio of products and partnerships focused on intracellular protein-protein interactions and other innovative approaches to addressing unmet medical needs. It was founded in 2008 and headquartered in Cambridge, Massachusetts.

#SimilarOrganizations #People #Financial #Website #More

RA PHARMACEUTICALS

Social Links:

Industry:
Biotechnology Medical Pharmaceutical

Founded:
2008-01-01

Address:
Cambridge, Massachusetts, United States

Country:
United States

Website Url:
http://www.rapharma.com

Total Employee:
5001+

Status:
Active

Contact:
617-401-4060

Email Addresses:
[email protected]

Total Funding:
226.93 M USD

Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail Google Maps Microsoft Azure DNS Google Maps API Microsoft Microsoft Azure New Relic Mobile Optimized


Similar Organizations

actinium-pharmaceuticals-logo

Actinium Pharmaceuticals

Actinium Pharmaceuticals develops alpha particle linked antibodies to treat cancer.

jounce-therapeutics-logo

Jounce Therapeutics

Jounce Therapeutics is developing cancer immune-therapies to harness the immune system to attack cancerous cells and tumors.

moderna-therapeutics-logo

Moderna Therapeutics

Moderna Therapeutics is a biotechnology company that specializes in drug discovery and drug development based on messenger RNA.

paxvax-logo

PaxVax

PaxVax is a start-up developing candidate oral vaccines for key infectious diseases.

phasebio-pharmaceuticals-logo

PhaseBio Pharmaceuticals

PhaseBio is a clinical-stage biopharmaceutical company that develops drugs for cardiovascular diseases, endocrine, and metabolic disorders.

salix-pharmaceuticals-logo

Salix Pharmaceuticals

Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.

synta-pharmaceuticals-logo

Synta Pharmaceuticals

Synta Pharmaceuticals is focused on developing and commercializing small molecule drugs to treat cancer and chronic inflammatory diseases.

tiburio-therapeutics-logo

Tiburio Therapeutics

Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.

zs-pharma-logo

ZS Pharma

ZS Pharma develops ion trap therapies for the treatment of life-threatening medical conditions such as hyperkalemia and liver diseases.


Current Advisors List

lauren-silverman_image

Lauren Silverman Member of the Board of Directors @ Ra Pharmaceuticals
Board_member

Founder


doug-treco_image

Doug Treco

jim-broderick_image

Jim Broderick

Stock Details


Company's stock symbol is NASDAQ:RARX

Investors List

rock-springs-capital_image

Rock Springs Capital

Rock Springs Capital investment in Series B - Ra Pharmaceuticals

morgenthaler-ventures_image

Morgenthaler Ventures

Morgenthaler Ventures investment in Series B - Ra Pharmaceuticals

amgen-ventures_image

Amgen Ventures

Amgen Ventures investment in Series B - Ra Pharmaceuticals

novo-ventures_image

Novo Ventures

Novo Ventures investment in Series B - Ra Pharmaceuticals

ra-capital-management_image

RA Capital Management

RA Capital Management investment in Series B - Ra Pharmaceuticals

new-enterprise-associates_image

New Enterprise Associates

New Enterprise Associates investment in Series B - Ra Pharmaceuticals

limulus-venture-partners_image

Limulus Venture Partners

Limulus Venture Partners investment in Series B - Ra Pharmaceuticals

lightstone-ventures_image

Lightstone Ventures

Lightstone Ventures investment in Series B - Ra Pharmaceuticals

novartis-venture-fund_image

Novartis Venture Fund

Novartis Venture Fund investment in Series B - Ra Pharmaceuticals

Official Site Inspections

http://www.rapharma.com Semrush global rank: 1.4 M Semrush visits lastest month: 20.35 K

  • Host name: 51.144.52.30
  • IP address: 51.144.52.30
  • Location: Amsterdam Netherlands
  • Latitude: 52.3534
  • Longitude: 4.9087
  • Timezone: Europe/Amsterdam
  • Postal: 1091

Loading ...

More informations about "Ra Pharmaceuticals"

Ra Pharmaceuticals Company Profile - Office Locations ... - Craft

Jul 23, 2018 · Ra Pharmaceuticals $3 m in annual revenue in FY 2019. See insights on Ra Pharmaceuticals including office locations, competitors, revenue, financials, executives, …See details»

Ra Pharmaceuticals - Crunchbase Company Profile

Ra Pharma is developing Cyclomimetics, a new drug class combining the properties and benefits of antibodies and small molecules. View contacts for Ra Pharmaceuticals to access new leads and connect with decision-makers.See details»

Ra Pharmaceuticals Company Profile 2024: Valuation, …

Ra Pharmaceuticals was founded in 2008. Where is Ra Pharmaceuticals headquartered? Ra Pharmaceuticals is headquartered in Cambridge, MA. What is the size of Ra Pharmaceuticals? Ra Pharmaceuticals has 89 total employees. …See details»

UCB completes the acquisition of Ra Pharmaceuticals – to deliver ...

Apr 2, 2020 · Ra Pharma, now a wholly-owned subsidiary of UCB, is a clinical-stage biopharmaceutical company leveraging a proprietary peptide chemistry platform to develop …See details»

Ra Pharmaceuticals Inc - Company Profile and News

Ra Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. The Company offers drugs for the treatment of cancer, inflammation and autoimmune disease, diabetes, and...See details»

UCB agrees to acquire Ra Pharmaceuticals: Joining forces to …

Oct 10, 2019 · Ra Pharma is a clinical-stage biopharmaceutical company leveraging a proprietary peptide chemistry platform to develop novel therapeutics for the treatment of serious diseases …See details»

RaPharma - VentureRadar

"Ra Pharma is a clinical-stage biopharmaceutical company focused on leading the field of complement biology to bring innovative and accessible therapies to patients with rare …See details»

UCB Completes the Acquisition of Ra Pharmaceuticals

BRUSSELS, April 2, 2020 /PRNewswire/ -- UCB today announced that the acquisition of Ra Pharmaceuticals, Inc. has been successfully completed and Ra Pharma is now a wholly-owned subsidiary of UCB....See details»

UCB sets sights on rare diseases giant Alexion with Ra Pharma ...

Oct 10, 2019 · UCB is to buy US biotech Ra Pharma in a deal worth around $2.1 billion, adding a late-stage treatment for the rare muscle weakness disease myasthenia gravis to its R&D …See details»

UCB acquires Ra Pharma for $2.1bn to enrich its rare …

Oct 11, 2019 · UCB has acquired Massachusetts-based Ra Pharmaceuticals for $48 per share, bringing the total transaction to a value of approximately $2.1bn. This deal is in line with UCB’s 2019 strategic growth path, and would bring Ra …See details»

UCB to acquire Ra Pharmaceuticals in $2.1bn deal

Belgian biopharmaceutical firm UCB has signed a merger agreement to acquire US-based Ra Pharmaceuticals for $48 per share, totalling $2.1bn in cash. Ra Pharma is developing treatments for serious diseases driven by abnormal …See details»

UCB Cuts $2.1 Billion Deal to Acquire Ra Pharma - the-scientist.com

Oct 14, 2019 · Brussels-based drugmaker UCB has agreed to acquire Massachusetts-based Ra Pharma for $2.1 billion, according to a joint statement published last week (October 10).See details»

UCB to Acquire Ra Pharma for $2.1B, Raising Rare Disease Presence

Oct 10, 2019 · Ra Pharma is recruiting patients for the Phase III RAISE trial ( NCT04115293 ), a multicenter, randomized, double-blind, placebo-controlled study designed to confirm the …See details»

UCB Acquires Ra Pharma, Adds Zilucoplan to Its MG Pipeline

Apr 21, 2020 · UCB has completed its acquisition of Ra Pharmaceuticals, priced at about $2.3 billion, meaning that zilucoplan — an investigational treatment for myasthenia gravis (MG) — …See details»

Ra Pharmaceuticals Earns Clinical Development Milestone for Oral ...

Aug 21, 2019 · Ra Pharmaceuticals is a clinical-stage biopharmaceutical company focused on leading the field of complement biology to bring innovative and accessible therapies to patients …See details»

UCB agrees to acquire Ra Pharmaceuticals: Joining forces to …

Ra Pharma is a clinical-stage biopharmaceutical company leveraging a proprietary peptide chemistry platform to develop novel therapeutics for the treatment of serious diseases caused …See details»

RaPharma | VentureRadar

Website: http://www.rapharma.com/ Ra Pharma is a clinical-stage biopharmaceutical company focused on leading the field of complement biology to bring innovative and accessible …See details»

UCB Agrees to Acquire Ra Pharmaceuticals: Joining ... - Business …

Oct 10, 2019 · Ra Pharma is a clinical-stage biopharmaceutical company leveraging a proprietary peptide chemistry platform to develop novel therapeutics for the treatment of serious diseases …See details»

Ra Pharmaceuticals Earns Clinical Development Milestone for Oral ...

Aug 21, 2019 · Ra Pharmaceuticals is a clinical-stage biopharmaceutical company focused on leading the field of complement biology to bring innovative and accessible therapies to patients …See details»

linkstock.net © 2022. All rights reserved